Deciphera Pharma's late-stage stomach cancer study meets main goal
Aug 13 (Reuters) - Deciphera Pharmaceuticals Inc DCPH.O said on Tuesday its late-stage study met the main goal of progression-free survival in patients with a form of stomach cancer.
The study tested the treatment, ripretinib, in 129 patients with advanced gastrointestinal stromal tumors.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Shinjini Ganguli)
((Aakash.B@thomsonreuters.com; within the U.S. +16462238780, outside the U.S. +91 80 67491576; Twitter: @JagadeeshAakash;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.